Recombinant Human Papillomavirus 11-valent Vaccine clinical trials
How each study uses Recombinant Human Papillomavirus 11-valent Vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
- 2
Studies by the year they started
3 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Recombinant Human Papillomavirus 11-valent Vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 18-45 YearsActive, not recruitingPhase 3National Vaccine and Serum Institute, ChinaNCT05262010Written as 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)How we know
- Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)CompletedPhase 2National Vaccine and Serum Institute, ChinaNCT04436133Written as Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)How we know
- A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 YearsCompletedPhase 1National Vaccine and Serum Institute, ChinaNCT04083196Written as 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)How we know